R3 reports first patient in next-gen drug-eluting scaffold study

R3 reports first patient in next-gen drug-eluting scaffold study

R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and Weill Cornell Medicine treated the first patient. The trial evaluates the company’s next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee peripheral arterial disease (PAD). Mountain View, California-based R3 designed Magnitude to…

R3 Vascular Announces First Patient Treated In ELITE-BTK Pivotal Trial For Below-the-Knee PAD Using MAGNITUDEÒ Drug Eluting Bioresorbable Scaffold - Medical Device News Magazine

The trial evaluates R3 Vascular’s next-generation drug-eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD, which according to the American Heart Association affects more than 200 million people globally, and 10 to 12 million in the U.S. older than the age of 40.  The most common type of PAD affects the lower-extremity where blood flow is reduced to the legs and feet.  Each year, approximately 150,000 leg amputations are per…